arrow
J

Jean-Sébastien Frenel

Institut de Cancerologie de l'Ouest Rene Gauducheau
H指数:38
被引数:8,286

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical features associated with exceptional response on first-line anti-HER2-based therapy for metastatic breast cancer: real-world data from the ESME national cohort

与转移性乳腺癌一线抗HER2为基础治疗中表现出非凡疗效相关的临床特征:来自ESME国家队列的真实世界数据

Breast
IF7.9
2026-10-130
OAAI
Chemotherapy outcomes in human epidermal growth factor receptor 2-low, hormone receptor-positive metastatic breast cancer: Insights from the French multicenter ESME database

人表皮生长因子受体2低表达、激素受体阳性转移性乳腺癌的化疗结局:来自法国多中心ESME数据库的见解

Breast
IF7.9
2026-09-270
OA
Efficacy and safety of immune checkpoint inhibitor rechallenge in cervical and endometrial cancer: a multi-center retrospective study (RICE study)

免疫检查点抑制剂再挑战在宫颈癌和子宫内膜癌中的疗效与安全性:一项多中心回顾性研究(RICE研究)

2026-07-150
PRE
Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study
2026-06-240
OAAI
Tucatinib in patients with HER2-positive advanced/metastatic breast cancer: a systematic literature review of real-world evidence

曲拉曲坦在HER2阳性晚期/转移性乳腺癌患者中的应用:一项真实世界证据的系统文献综述

2026-06-090
OAAI
Characteristics, treatment and survival of older patients with metastatic triple negative breast cancer from the ESME mBC real-world national cohort: a comparison with younger women

老年转移性三阴性乳腺癌患者的特征、治疗及生存情况:基于ESME mBC真实世界全国队列研究,并与年轻女性进行比较

2026-05-220
OAAI
Characteristics and outcomes of patients with HER2-negative metastatic breast cancers with low expression of estrogen and progesterone receptors in the multicenter ESME cohort.

HER2阴性低表达雌激素和孕激素受体转移性乳腺癌患者的特征和结局:多中心ESME队列研究

2026-05-180
OAAI
BRCA1/2, PALB2 mutations and first-line CDK4/6 inhibitor efficacy in HR+ metastatic breast cancer

BRCA1/2、PALB2基因突变与HR+转移性乳腺癌中一线CDK4/6抑制剂疗效

2026-02-160
OAAI
Favourable long-term outcomes in selected HER2-Positive early breast cancer patients without pathological complete response after neoadjuvant chemotherapy and trastuzumab: A pre-T-DM1 era cohort study

在未获得病理完全缓解的HER2阳性早期乳腺癌患者中,新辅助化疗联合曲妥珠单抗治疗后的长期预后良好:一项预T-DM1时代的队列研究

2026-01-010
OAAI
Recent treatment and survival trends in older versus younger women with HR-positive HER2-negative metastatic breast cancer in the real-life multicenter French ESME cohort

老年与年轻HR阳性HER2阴性转移性乳腺癌女性患者真实世界多中心法国ESME队列中的近期治疗与生存趋势

2025-12-050
PRE
PROMENADE: pembrolizumab for early ER-low/HER2-negative breast cancer, real-world French cohort

PROMENADE研究:早期ER低表达/HER2阴性乳腺癌患者接受pembrolizumab治疗的真实世界法国队列研究

2025-11-250
OAAI
Nivolumab in combination with ipilimumab versus capecitabine as post-operative treatment for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy: a multicentre, randomized, open-label phase II trial – BREASTIMMUNE-03

纳武利尤单抗联合伊匹木单抗与卡培他滨作为新辅助化疗后仍有残留病灶的三阴性乳腺癌患者的术后治疗:一项多中心、随机、开放标签的II期试验——BREASTIMMUNE-03

2025-11-210
OAAI
Association between molecular classification and overall survival in patients with metastatic endometrial carcinoma: ancillary results of the UTOLA phase II GINECO trial.

转移性子宫内膜癌患者中分子分型与总生存期的关联:UTOLA II期GINECO试验的辅助结果。

2025-11-210
PRE
Real-world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR-positive/HER2-negative metastatic breast cancer in the ESME-MBC cohort

CDK4/6抑制剂治疗后疾病进展的HR阳性/HER2阴性转移性乳腺癌患者中真实世界的治疗模式与疗效:ESME-MBC队列研究

2025-09-170
PREAI
Patritumab deruxtecan in HR+HER2− advanced breast cancer: a phase 2 trial

帕梯他马单抗德鲁克替康在HRHER2+−晚期乳腺癌中的治疗:一项II期临床试验

2025-09-040
OAAI
Selective disruption of DNMT1/ELK1 interactions induces DGKI re-expression and promotes temozolomide sensitivity of MGMTmethylated/DGKImethylated glioblastoma

选择性破坏DNMT1/ELK1相互作用可诱导DGKI再表达,并增强MGMT甲基化/DGKI甲基化胶质母细胞瘤对替莫唑胺的敏感性。

2025-09-010
OAAI